ArticleFrontiers in microbiology2021
Discovering the Potentials of Four Phage Endolysins to Combat Gram-Negative Infections.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 46 citations in OpenAlex.
- Bacteriophages in the treatment of cutaneous infections and skin disorders: therapeutic advances and future directions.Clinical microbiology reviews · 2026Review
- Phage and endolysin-based inhibition ofFrontiers in cellular and infection microbiology · 2026Review
- Wound-Healing Potential of Engineered Lysin GRC-ML07 inAntibiotics (Basel, Switzerland) · 2025Article
- Review
- CombatingFrontiers in cellular and infection microbiology · 2025Review
- Comprehensive Approaches to CombattingAntibiotics (Basel, Switzerland) · 2024Review
- Development of novel antimicrobials with engineered endolysin LysECD7-SMAP to combat Gram-negative bacterial infections.Journal of biomedical science · 2024Article
- LysJEP8: A promising novel endolysin for combating multidrug-resistant Gram-negative bacteria.Microbial biotechnology · 2024Article
- Article
- Combined effect of SAR-endolysin LysKpV475 with polymyxin B andMicrobiology (Reading, England) · 2024Article
- Biofilm-disrupting effects of phage endolysins LysAm24, LysAp22, LysECD7, and LysSi3: breakdown the matrix.World journal of microbiology & biotechnology · 2024Article
- Anti-Biofilm Strategies: A Focused Review on Innovative Approaches.Microorganisms · 2024Review
- Alginate Gel Encapsulated with Enzybiotics Cocktail Is Effective against Multispecies Biofilms.Gels (Basel, Switzerland) · 2024Article
- Endolysins: a new antimicrobial agent against antimicrobial resistance. Strategies and opportunities in overcoming the challenges of endolysins against Gram-negative bacteria.Frontiers in pharmacology · 2024Review
- PlyKp104, a Novel Phage Lysin for the Treatment of Klebsiella pneumoniae, Pseudomonas aeruginosa, and Other Gram-Negative ESKAPE Pathogens.Antimicrobial agents and chemotherapy · 2023Article
- Antibacterial activity of vB_AbaM_PhT2 phage hydrophobic amino acid fusion endolysin, combined with colistin against Acinetobacter baumannii.Scientific reports · 2023Article
- Structural and functional features of a broad-spectrum prophage-encoded enzybiotic from Enterococcus faecium.Scientific reports · 2023Article
- Recent Progress in Phage Therapy to Modulate Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2022Review
- Complete Genome Sequence of Pseudomonas aeruginosa Bacteriophage PASA16, Used in Multiple Phage Therapy Treatments Globally.Microbiology resource announcements · 2022Article
- Essential Topics for the Regulatory Consideration of Phages as Clinically Valuable Therapeutic Agents: A Perspective from Spain.Microorganisms · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 6 institutions in 1 country.
Daria V VasinaLaboratory of Pathogen Population Variability Mechanisms, N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia.
Nataliia P AntonovaLaboratory of Pathogen Population Variability Mechanisms, N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia.
Igor V GrigorievTranslational Biomedicine Laboratory, N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia.
Victoria S YakimakhaFaculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
Anastasiya M LendelLaboratory of Pathogen Population Variability Mechanisms, N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia.
Maria A NikiforovaLaboratory of Pathogen Population Variability Mechanisms, N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia.
Andrei A PochtovyiLaboratory of Pathogen Population Variability Mechanisms, N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia.
Timofey A RemizovTranslational Biomedicine Laboratory, N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia.
Evgeny V UsachevLaboratory of Pathogen Population Variability Mechanisms, N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia.
Natalia V ShevlyaginaLaboratory of Indication and Ultrastructural Analysis of Microorganisms, N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia.
Vladimir G ZhukhovitskyLaboratory of Indication and Ultrastructural Analysis of Microorganisms, N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia.
Mikhail V FursovAerobiological Laboratory, State Research Center for Applied Microbiology and Biotechnology, Obolensk, Russia.
Vasiliy D PotapovAerobiological Laboratory, State Research Center for Applied Microbiology and Biotechnology, Obolensk, Russia.
Aleksei M VorobevLaboratory of Clinical Microbiology and Biotechnology of Bacteriophages, G. N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology, Moscow, Russia.
Andrey V AleshkinLaboratory of Clinical Microbiology and Biotechnology of Bacteriophages, G. N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology, Moscow, Russia.
Aleksei I LaishevtsevLaboratory for Diagnostics and Control of Antibiotic Resistance of the Most Clinically Significant Pathogens of Animals, Federal State Budget Scientific Institution "Federal Scientific Centre VIEV" (FSC VIEV), Moscow, Russia.
Valentine V MakarovCenter for Strategic Planning of the Ministry of Health of the Russian Federation, Moscow, Russia.
Sergey M YudinCenter for Strategic Planning of the Ministry of Health of the Russian Federation, Moscow, Russia.
Artem P TkachukTranslational Biomedicine Laboratory, N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia.
Vladimir A GushchinLaboratory of Pathogen Population Variability Mechanisms, N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia.
Ministry of Health of the Russian Federation · RUGabrichevsky Institute of Epidemiology and Microbiology · RULomonosov Moscow State University · RUState Research Center for Applied Microbiology and Biotechnology · RUAll-Russian Scientific Research Institute of Experimental Veterinary Sciences. Ya.R. Kovalenko · RUCenter for Strategic Research · RU
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endolysin-based therapeutics are promising antibacterial agents and can successfully supplement the existing antibacterial drugs array. It is specifically important in the case of Gram-negative pathogens, e.g., ESKAPE group bacteria, which includes
Indexed as
animal modelsantimicrobial agentsendolysinGram-negative bacterialocal infectionsafety
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.